249 related articles for article (PubMed ID: 26981779)
1. Genomic portfolio of Merkel cell carcinoma as determined by comprehensive genomic profiling: implications for targeted therapeutics.
Cohen PR; Tomson BN; Elkin SK; Marchlik E; Carter JL; Kurzrock R
Oncotarget; 2016 Apr; 7(17):23454-67. PubMed ID: 26981779
[TBL] [Abstract][Full Text] [Related]
2. Genomic landscape of salivary gland tumors.
Kato S; Elkin SK; Schwaederle M; Tomson BN; Helsten T; Carter JL; Kurzrock R
Oncotarget; 2015 Sep; 6(28):25631-45. PubMed ID: 26247885
[TBL] [Abstract][Full Text] [Related]
3. Next generation sequencing of Cytokeratin 20-negative Merkel cell carcinoma reveals ultraviolet-signature mutations and recurrent TP53 and RB1 inactivation.
Harms PW; Collie AM; Hovelson DH; Cani AK; Verhaegen ME; Patel RM; Fullen DR; Omata K; Dlugosz AA; Tomlins SA; Billings SD
Mod Pathol; 2016 Mar; 29(3):240-8. PubMed ID: 26743471
[TBL] [Abstract][Full Text] [Related]
4. Genomic Alterations and Tumor Mutation Burden in Merkel Cell Carcinoma.
Brazel D; Kumar P; Doan H; Pan T; Shen W; Gao L; Moyers JT
JAMA Netw Open; 2023 Jan; 6(1):e2249674. PubMed ID: 36602798
[TBL] [Abstract][Full Text] [Related]
5. The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy.
Knepper TC; Montesion M; Russell JS; Sokol ES; Frampton GM; Miller VA; Albacker LA; McLeod HL; Eroglu Z; Khushalani NI; Sondak VK; Messina JL; Schell MJ; DeCaprio JA; Tsai KY; Brohl AS
Clin Cancer Res; 2019 Oct; 25(19):5961-5971. PubMed ID: 31399473
[TBL] [Abstract][Full Text] [Related]
6. An analysis of the use of targeted therapies in patients with advanced Merkel cell carcinoma and an evaluation of genomic correlates of response.
Knepper TC; Panchaud RA; Muradova E; Cohen L; DeCaprio JA; Khushalani NI; Tsai KY; Brohl AS
Cancer Med; 2021 Sep; 10(17):5889-5896. PubMed ID: 34269527
[TBL] [Abstract][Full Text] [Related]
7. Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy.
Goh G; Walradt T; Markarov V; Blom A; Riaz N; Doumani R; Stafstrom K; Moshiri A; Yelistratova L; Levinsohn J; Chan TA; Nghiem P; Lifton RP; Choi J
Oncotarget; 2016 Jan; 7(3):3403-15. PubMed ID: 26655088
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous squamous and neuroendocrine carcinoma: genetically and immunohistochemically different from Merkel cell carcinoma.
Pulitzer MP; Brannon AR; Berger MF; Louis P; Scott SN; Jungbluth AA; Coit DG; Brownell I; Busam KJ
Mod Pathol; 2015 Aug; 28(8):1023-32. PubMed ID: 26022453
[TBL] [Abstract][Full Text] [Related]
9. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
Groisberg R; Hong DS; Holla V; Janku F; Piha-Paul S; Ravi V; Benjamin R; Kumar Patel S; Somaiah N; Conley A; Ali SM; Schrock AB; Ross JS; Stephens PJ; Miller VA; Sen S; Herzog C; Meric-Bernstam F; Subbiah V
Oncotarget; 2017 Jun; 8(24):39254-39267. PubMed ID: 28424409
[TBL] [Abstract][Full Text] [Related]
10. Next-generation sequencing of salivary high-grade neuroendocrine carcinomas identifies alterations in RB1 and the mTOR pathway.
Goyal B; Duncavage EJ; Martinez D; Lewis JS; Chernock RD
Exp Mol Pathol; 2014 Dec; 97(3):572-8. PubMed ID: 25446844
[TBL] [Abstract][Full Text] [Related]
11. Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing.
Ikeda S; Elkin SK; Tomson BN; Carter JL; Kurzrock R
Cancer Biol Ther; 2019; 20(2):219-226. PubMed ID: 30339521
[TBL] [Abstract][Full Text] [Related]
12. Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing.
Janku F; Kaseb AO; Tsimberidou AM; Wolff RA; Kurzrock R
Oncotarget; 2014 May; 5(10):3012-22. PubMed ID: 24931142
[TBL] [Abstract][Full Text] [Related]
13. Genomic Profiling of Parathyroid Carcinoma Reveals Genomic Alterations Suggesting Benefit from Therapy.
Kang H; Pettinga D; Schubert AD; Ladenson PW; Ball DW; Chung JH; Schrock AB; Madison R; Frampton GM; Stephens PJ; Ross JS; Miller VA; Ali SM
Oncologist; 2019 Jun; 24(6):791-797. PubMed ID: 30373905
[TBL] [Abstract][Full Text] [Related]
14. A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice.
Vasan N; Yelensky R; Wang K; Moulder S; Dzimitrowicz H; Avritscher R; Wang B; Wu Y; Cronin MT; Palmer G; Symmans WF; Miller VA; Stephens P; Pusztai L
Oncologist; 2014 May; 19(5):453-8. PubMed ID: 24710307
[TBL] [Abstract][Full Text] [Related]
15. On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients.
Schwaederle M; Daniels GA; Piccioni DE; Fanta PT; Schwab RB; Shimabukuro KA; Parker BA; Kurzrock R
Mol Cancer Ther; 2015 Jun; 14(6):1488-94. PubMed ID: 25852059
[TBL] [Abstract][Full Text] [Related]
16. Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine.
Subbiah V; Wagner MJ; McGuire MF; Sarwari NM; Devarajan E; Lewis VO; Westin S; Kato S; Brown RE; Anderson P
Oncotarget; 2015 Dec; 6(38):40642-54. PubMed ID: 26510912
[TBL] [Abstract][Full Text] [Related]
17. UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas.
Wong SQ; Waldeck K; Vergara IA; Schröder J; Madore J; Wilmott JS; Colebatch AJ; De Paoli-Iseppi R; Li J; Lupat R; Semple T; Arnau GM; Fellowes A; Leonard JH; Hruby G; Mann GJ; Thompson JF; Cullinane C; Johnston M; Shackleton M; Sandhu S; Bowtell DD; Johnstone RW; Fox SB; McArthur GA; Papenfuss AT; Scolyer RA; Gill AJ; Hicks RJ; Tothill RW
Cancer Res; 2015 Dec; 75(24):5228-34. PubMed ID: 26627015
[TBL] [Abstract][Full Text] [Related]
18. Genomic Landscape of Malignant Mesotheliomas.
Kato S; Tomson BN; Buys TP; Elkin SK; Carter JL; Kurzrock R
Mol Cancer Ther; 2016 Oct; 15(10):2498-2507. PubMed ID: 27507853
[TBL] [Abstract][Full Text] [Related]
19. Hotspot mutations in polyomavirus positive and negative Merkel cell carcinomas.
Veija T; Sarhadi VK; Koljonen V; Bohling T; Knuutila S
Cancer Genet; 2016; 209(1-2):30-5. PubMed ID: 26725423
[TBL] [Abstract][Full Text] [Related]
20. Clinical implications of prospective genomic profiling of metastatic breast cancer patients.
van Geelen CT; Savas P; Teo ZL; Luen SJ; Weng CF; Ko YA; Kuykhoven KS; Caramia F; Salgado R; Francis PA; Dawson SJ; Fox SB; Fellowes A; Loi S
Breast Cancer Res; 2020 Aug; 22(1):91. PubMed ID: 32811538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
